Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market

Novo Nordisk Nyheter

Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Eli Lilly,Amgen,Market Leaders

Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.

  • 📰 YahooFinanceCA
  • ⏱ Reading Time:
  • 45 sec. here
  • 8 min. at publisher
  • 📊 Quality Score:
  • News: 42%
  • Publisher: 63%

) positive trial results update on its GLP-1 injectable for obesity, MariTide, sent its stock up more than 13% in trading Friday.

Eli Lilly CEO David Ricks similarly noted that it was really a matter of making the right moves to maintain the market lead.Both companies have early-stage next-generation products in the pipeline in addition to the clinical trials for expanded uses of current products. Louis Gossett Jr. fought a years-long battle with the disease but died on March 29, according to a family member.Killer TD variable rate mortgage could be sign of better deals to come

"Being really open about quite personal things I think is really important," the actress said at the King's Trust Gala on May 2You can expect to earn reliable monthly passive income for years to come by investing in these two top Canadian monthly dividend stocks now. The post Monthly Income Masters: 2 Canadian Stocks Paying Steady Dividends Every 30 Days appeared first on The Motley Fool Canada.

Vi har sammanfattat den här nyheten så att du kan läsa den snabbt. Om du är intresserad av nyheterna kan du läsa hela texten här. Läs mer:

YahooFinanceCA /  🏆 47. in SE
 

Sverige Senaste nytt, Sverige Rubriker



Render Time: 2025-01-13 17:11:02